
Please try another search
Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. It offers Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; KYNMOBI a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson’s disease; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. The company’s proprietary pipeline products include Anaphylm, an epinephrine sublingual film, which is in phase 3 clinical trial for the emergency treatment of allergic reactions, including anaphylaxis; and AQST-108, a topical gel that is in phase 2 clinical trial for the treatment of alopecia areata. In addition, it develops PharmFilm technology for patients suffering from certain central nervous system disorders; and Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.
Name | Age | Since | Title |
---|---|---|---|
Gregory Bailey Brown | 71 | 2007 | Independent Chairman of the Board |
John Shannon Cochran | 59 | 2004 | Independent Vice Chairman of the Board |
Daniel Barber | 48 | 2014 | CEO, President & Director |
David M. Fleischer | - | 2022 | Member of Scientific Advisory Board |
Marco Taglietti | 64 | 2021 | Independent Director |
Carlos Camargo | - | 2022 | Member of Scientific Advisory Board |
Matthew Greenhawt | - | 2022 | Member of Scientific Advisory Board |
Ruchi S. Gupta | - | 2022 | Member of Scientific Advisory Board |
Julie Krop | 58 | 2021 | Independent Director |
Timothy E. Morris | 63 | 2022 | Independent Director |
David B. Golden | - | 2022 | Member of Scientific Advisory Board |
John Oppenheimer | - | 2022 | Member of Scientific Advisory Board |
Abigail L. Jenkins | 48 | 2024 | Independent Director |
Jay Lieberman | - | 2022 | Member of Scientific Advisory Board |
David I. Bernstein | - | 2022 | Member of Scientific Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review